ZZ Biotech’s Stroke Drug Moves Closer to Pivotal Phase 3 Clinical Trial as the NIH Awards First Tranche of $30 Million Grant to the Keck School of Medicine of USC
3K3A-APC Granted Fast-Track Designation by FDA with Multinational Clinical Trial to Run Through NIH StrokeNet Houston, May 24, 2022, — In a significant development for the treatment of acute ischemic stroke, the National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health (NIH), awarded the first $4 million of…
Read MoreZZ Biotech Announces First Patients Dosed in Phase 2 Clinical Trial of 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Houston, TX December 2, 2021 — ZZ Biotech, a clinical stage biopharmaceutical company developing the experimental drug 3K3A-APC for some of the biggest unmet needs in stroke, neurodegenerative disease and chronic wound healing, today announced that the first patients have been dosed in a Phase 2 clinical trial evaluating 3K3A-APC for the treatment of amyotrophic…
Read MoreZZ Biotech Announces FDA Fast Track Designation for Stroke Program
HOUSTON, June 12, 2020—ZZ Biotech today announced that the US Food and Drug Administration (FDA) has designated the investigation of the company’s experimental drug 3K3A-APC for the treatment of acute ischemic stroke as a Fast Track development program. ZZ Biotech’s 3K3A-APC is a genetically engineered variant of the naturally occurring activated Protein C, which plays…
Read MoreZZ Biotech Announces Preliminary Phase 2 Stroke Trial Results with 3K3A-APC
HOUSTON, January 26, 2018—ZZ Biotech today announced that preliminary results of RHAPSODY, the company’s Phase 2 clinical trial in acute ischemic stroke patients, were presented at the 2018 International Stroke Conference in Los Angeles. The placebo-controlled dose-escalation trial was designed to establish a maximally tolerated dose (MTD) of 3K3A-APC in patients with acute ischemic stroke…
Read MoreHope for reversing stroke-induced long-term disability
A human protein combined with stem cell therapy has been found to repair stroke damage to the brain, according to a new USC-led study on mice. Permanent brain damage from a stroke may be reversible thanks to a developing therapeutic technique, a USC-led study has found.
Read MoreStem cell therapy heals injured mouse brain
Animal study examines method for restoring brain cells killed by stroke or other neurological diseases Scientists and clinicians have long dreamed of helping the injured brain repair itself by creating new neurons, and an innovative NIH-funded study published today in Nature Medicine may bring this goal much closer to reality. A team of researchers has…
Read MoreZZ Biotech’s regenerative bio drugs manufactured in Brisbane with support of Biopharmaceuticals Australia
ZZ Biotech was awarded a $250,000 grant by BPA to support clinical development of its lead drug product, 3K3A-APC. The drug was manufactured at Patheon’s state-of-the-art contract manufacturing located in Brisbane, and will be used in animal studies and Phase 2 clinical trials targeting ischemic stroke and diabetic foot ulcers.
Read MoreZZ Biotech Acquires Bioatrix
In December 2015, US company ZZ Biotech LLC completed the acquisition of Bioatrix Pty Ltd. Based in Houston, ZZ Biotech is in a Phase 2 trial with 3K3A-Activated Protein C (‘3K3A-APC’) in acute ischemic stroke patients, supported by a grant from the National Institute for Neurological Disease and Stroke. ZZ Biotech’s Australian subsidiary is presently…
Read More$8 Million NIH Grant Will Fund Multicenter Clinical Trial of Stroke Intervention Drug
Award to Cedars-Sinai Stroke Intervention Researchers Supports Collaborative Study Involving National Institute of Neurological Disorders and Stroke LOS ANGELES (April 22, 2014) – Cedars-Sinai stroke intervention researchers have been informed that the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, will award an $8 million grant to fund a…
Read MoreZZ Biotech Announces Phase 2 Trial with 3K3A-APC in Stroke
ZZ Biotech Announces Phase 2 Trial with 3K3A-APC in Stroke; Funds Will Be Provided by NIH and Broadview Ventures HOUSTON, April 22, 2014—ZZ Biotech today announced that the National Institutes of Health will support a multicenter Phase 2 clinical trial of its experimental drug, 3K3A-APC, in patients suffering from acute ischemic stroke. The Phase 2…
Read More